Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01033032 · ClinicalTrials.gov registry record · Phase 1
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT01033032 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 78 participants.
The verdict
NCT01033032, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
Doxorubicin has been an integral part of the treatment of women with breast cancer for many years. Since amrubicin may have more activity than doxorubicin, as well as less cardiotoxicity, evaluation of amrubicin in the treatment of advanced breast cancer should be a priority. In this Phase II study, the investigators propose an evaluation of single-agent amrubicin as second- or third-line treatment for women with metastatic breast cancer.
Interventions
- DRUG Amrubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01033032
The ClinicalTrials.gov registry entry for NCT01033032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amrubicin is the first listed.
NCT01033032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01033032 about?
NCT01033032 is a clinical study titled "Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer". Doxorubicin has been an integral part of the treatment of women with breast cancer for many years. Since amrubicin may have more activity than doxorubicin, as well as less cardiotoxicity, evaluation of amrubicin in the treatment of advanced breast cancer should be a priority. In this Phase II study,...
What is the current status of trial NCT01033032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2009-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01033032?
The interventions under investigation include: Amrubicin (DRUG).
Who is sponsoring clinical trial NCT01033032?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.